Literature DB >> 19444222

Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans.

Kimberly J Schmitz1, Halcyon G Skinner, Leonelo E Bautista, Tasha E Fingerlin, Carl D Langefeld, Pamela J Hicks, Steven M Haffner, Michael Bryer-Ash, Lynne E Wagenknecht, Donald W Bowden, Jill M Norris, Corinne D Engelman.   

Abstract

BACKGROUND: Several observational studies have recently suggested an inverse association of circulating levels of vitamin D with blood pressure. These findings have been based mainly on Caucasian populations; whether this association also exists among Hispanic and African Americans has yet to be definitively determined. This study investigates the association of 25-hydroxyvitamin D (25[OH]D) with blood pressure in Hispanic and African Americans.
METHODS: The data source for this study is the Insulin Resistance Atherosclerosis Family Study (IRASFS), which consists of Hispanic- and African-American families from three US recruitment centers (n =1,334). A variance components model was used to analyze the association of plasma 25[OH]D levels with blood pressure.
RESULTS: An inverse association was found between 25[OH]D and both systolic (beta for 10 ng/ml difference = -2.05; P < 0.01) and diastolic (beta for 10 ng/ml difference = -1.35; P < 0.001) blood pressure in all populations combined, after adjusting for age, sex, ethnicity, and season of blood draw. Further adjustment for body mass index (BMI) weakened this association (beta for 10 ng/ml difference = -0.94; P = 0.14 and beta for 10 ng/ml difference = -0.64; P = 0.09, respectively).
CONCLUSIONS: 25[OH]D levels are significantly inversely associated with blood pressure in Hispanic and African Americans from the IRASFS. However, this association was not significant after adjustment for BMI. Further research is needed to determine the role of BMI in this association. Large, well-designed prospective studies of the effect of vitamin D supplementation on blood pressure may be warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444222      PMCID: PMC2865679          DOI: 10.1038/ajh.2009.88

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  22 in total

1.  Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods.

Authors:  Leora Henkin; Richard N Bergman; Donald W Bowden; Darrell L Ellsworth; Steven M Haffner; Carl D Langefeld; Braxton D Mitchell; Jill M Norris; Marian Rewers; Mohammed F Saad; Elizabeth Stamm; Lynne E Wagenknecht; Stephen S Rich
Journal:  Ann Epidemiol       Date:  2003-04       Impact factor: 3.797

2.  Plasma ionized calcium and cardiovascular risk factors in mild primary hyperparathyroidism: effects of long-term treatment with active vitamin D (alphacalcidol).

Authors:  L Lind; B Wengle; H Lithell; S Ljunghall
Journal:  J Intern Med       Date:  1992-04       Impact factor: 8.989

3.  Comparison of two methods of assessing physical activity in the Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Authors:  S Sidney; D R Jacobs; W L Haskell; M A Armstrong; A Dimicco; A Oberman; P J Savage; M L Slattery; B Sternfeld; L Van Horn
Journal:  Am J Epidemiol       Date:  1991-06-15       Impact factor: 4.897

4.  Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women.

Authors:  M Pfeifer; B Begerow; H W Minne; D Nachtigall; C Hansen
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

5.  Influence of ultraviolet irradiation on plasma vitamin D and calcitonin levels in humans.

Authors:  F Kokot; H Schmidt-Gayk; A Wiecek; Z Mleczko; B Bracel
Journal:  Kidney Int Suppl       Date:  1989-11       Impact factor: 10.545

6.  PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight.

Authors:  M F McCarty; C A Thomas
Journal:  Med Hypotheses       Date:  2003 Nov-Dec       Impact factor: 1.538

7.  Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance.

Authors:  L Lind; H Lithell; E Skarfors; L Wide; S Ljunghall
Journal:  Acta Med Scand       Date:  1988

8.  Low circulating vitamin D in obesity.

Authors:  Y Liel; E Ulmer; J Shary; B W Hollis; N H Bell
Journal:  Calcif Tissue Int       Date:  1988-10       Impact factor: 4.333

9.  Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure.

Authors:  L Lind; T Pollare; A Hvarfner; H Lithell; O H Sørensen; S Ljunghall
Journal:  Diabetes Res       Date:  1989-07

10.  Evidence for alteration of the vitamin D-endocrine system in obese subjects.

Authors:  N H Bell; S Epstein; A Greene; J Shary; M J Oexmann; S Shaw
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

View more
  19 in total

Review 1.  Vitamin D: roles in renal and cardiovascular protection.

Authors:  Yan C Li
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

2.  Serum vitamin D level and prehypertension among subjects free of hypertension.

Authors:  Charumathi Sabanayagam; Anoop Shankar; Shanmugasundaram Somasundaram
Journal:  Kidney Blood Press Res       Date:  2011-09-21       Impact factor: 2.687

3.  Vitamin D intake is inversely related to risk of developing metabolic syndrome in African American and white men and women over 20 y: the Coronary Artery Risk Development in Young Adults study.

Authors:  Grace J Fung; Lyn M Steffen; Xia Zhou; Lisa Harnack; Weihong Tang; Pamela L Lutsey; Catherine M Loria; Jared P Reis; Linda V Van Horn
Journal:  Am J Clin Nutr       Date:  2012-05-30       Impact factor: 7.045

Review 4.  The uncertain significance of low vitamin D levels in African descent populations: a review of the bone and cardiometabolic literature.

Authors:  Michelle Y O'Connor; Caroline K Thoreson; Natalie L M Ramsey; Madia Ricks; Anne E Sumner
Journal:  Prog Cardiovasc Dis       Date:  2013 Nov-Dec       Impact factor: 8.194

5.  Circulating 25-hydroxyvitamin D levels in relation to blood pressure parameters and hypertension in the Shanghai Women's and Men's Health Studies.

Authors:  Tsogzolmaa Dorjgochoo; Xiao Ou Shu; Yong-Bing Xiang; Gong Yang; Qiuyin Cai; Honglan Li; Bu-Tian Ji; Hui Cai; Yu-Tang Gao; Wei Zheng
Journal:  Br J Nutr       Date:  2012-02-27       Impact factor: 3.718

6.  Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease : A meta-analysis.

Authors:  X Hu; J Shang; W Yuan; S Zhang; Y Jiang; B Zhao; Y Duan; J Xiao; Z Zhao
Journal:  Herz       Date:  2017-08-23       Impact factor: 1.443

Review 7.  Vitamin D deficiency in the pathogenesis of hypertension: still an unsettled question.

Authors:  Stephen G Rostand
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

8.  Effect of 1,25(OH)2D3 on transdifferentiation of rat renal tubular epithelial cells induced by high glucose.

Authors:  Hongtao Hu; Shen Xu; Shuang Hu; Yue Gao; Hua Shui
Journal:  Biomed Rep       Date:  2016-11-01

Review 9.  Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions.

Authors:  Roger Bouillon; Claudio Marcocci; Geert Carmeliet; Daniel Bikle; John H White; Bess Dawson-Hughes; Paul Lips; Craig F Munns; Marise Lazaretti-Castro; Andrea Giustina; John Bilezikian
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

10.  Vitamin d, adiposity, and calcified atherosclerotic plaque in african-americans.

Authors:  Barry I Freedman; Lynne E Wagenknecht; Kristen G Hairston; Donald W Bowden; J Jeffrey Carr; R Caresse Hightower; Ethel J Gordon; Jianzhao Xu; Carl D Langefeld; Jasmin Divers
Journal:  J Clin Endocrinol Metab       Date:  2010-01-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.